Work

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

Year: 2012

Type: article

Abstract: This commentary provides the authors' perspective on the article "Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial," which has recently been published in The Lancet Oncology.

Source: OncoImmunology

DOI: 10.4161/onci.20591

Authors: Ravi A Madan, Christopher R. Heery, James L. Gulley

Institutions: National Institutes of Health, National Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913